Has Neil Woodford lost the plot?

After a spate of dramatic falls in some of his biggest shareholdings, has renowned investor Neil Woodford finally lost the plot?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Britain’s best-known fund manager Neil Woodford has come in for a lot of flak in recent weeks. There’s been a rising tide of criticism from investors in his funds and media commentators. Indeed, some have gone as far as to ask whether one of the country’s most successful and longest-serving fund managers has finally lost the plot.

Impressive long-term record

In a two-and-a-half decade career at Invesco Perpetual, Woodford built an impressive record, delivering an annualised compound return of over 14%, outperforming the wider market by about 5% a year.

Having left Invesco to form his own fund management business in 2014, many of his loyal followers switched their investment into his new flagship Woodford Equity Income fund. They weren’t disappointed, with the fund ranking top of the UK equity income sector over its first year. It was business as usual.

Big hits to big holdings

However, it’s been a very different story over the last 12 months. According to fund tracker Trustnet, the Woodford Equity Income fund sits bottom of 84 funds in the sector and is the only one to have posted a negative return over the period.

The performance has been particularly impacted by recent big hits to some of his biggest blue-chip conviction bets, which have also hurt his Income Focus fund that launched just a few months ago.

His largest holding Astra Zeneca (over 8% of his Equity Income fund) suffered its biggest ever one-day fall in July, plunging 16% after the failure of a key cancer treatment trial. This was swiftly followed by a 9% hit to Imperial Brands — another top five holding — after the US Food and Drugs Administration announced plans to slash nicotine levels in cigarettes. Last but not least, fellow top five holding Provident Financial crashed 66% after releasing a disastrous profit warning.

Meanwhile, Woodford’s growth-oriented Patient Capital Trust, which launched in April 2015 at 100p a share, is currently trading at 97p, leading one wag over at FT Alphaville to comment: “Think it’s being renamed Very Patient Capital.” Its portfolio of “disruptive early-stage and early-growth companies” (many of which feature as a long tail of small holdings in his Equity Income fund) has also seen a number of spectacular blow-ups — Halosource, RM2 International and Sphere Medical to name but three.

Sticking to his guns

Despite the recent criticism, Woodford is sticking to his guns. He remains convinced of the attractions of AstraZeneca, Imperial Brands and, yes, even Provident Financial and believes “their share prices are sitting way below their fundamental value.” Likewise, he’s unperturbed by the share price of Patient Capital Trust. He believes the portfolio is “in excellent shape” and remains “very confident in the trust’s long-term return outlook.”

Of course, Woodford has underperformed at times in the past, picked some stocks that didn’t work out and had critics who suggested he’d lost the plot. “What’s he doing buying dull tobacco stocks when everyone knows dotcom businesses are the place to be?” “What’s he doing shunning banks when they’re delivering such good returns [pre-2008]?” History has provided the answer to those questions. And it suggests that the cries of “you don’t know what you’re doing” currently ringing out from some quarters will likely prove well wide of the mark.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca and Imperial Brands. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

Just released: our top 3 small-cap stocks to consider buying in October [PREMIUM PICKS]

Small-cap shares tend to be more volatile than larger companies, so we suggest investors should look to build up a…

Read more »

Investing Articles

How I’d use an empty Stocks and Shares ISA to aim for a £1,000 monthly passive income

Here's how using a Stocks and Shares ISA really could help those of us who plan to invest for an…

Read more »

Investing Articles

This FTSE stock is up 20% and set for its best day ever! Time to buy?

This Fool takes a look at the half-year results from Burberry (LON:BRBY) to see if the struggling FTSE stock might…

Read more »

Investing Articles

This latest FTSE 100 dip could be an unmissable opportunity to pick up cut-price stocks

The FTSE 100 has pulled back with the government’s policy choices creating some negative sentiment. But this gives us a…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

As the WH Smith share price falls 4% on annual results, is it still worth considering?

WH Smith took a hit after this morning’s results left shareholders unimpressed. With the share price down 4%, Mark Hartley…

Read more »

Investing Articles

The Aviva share price just jumped 4.5% but still yields 7.02%! Time to buy?

A positive set of results has put fresh life into the Aviva share price. Harvey Jones says it offers bags…

Read more »

Investing Articles

Can a €500m buyback kickstart the Vodafone share price?

The Vodafone share price has been a loser for investors in recent years, and the dividend has been cut. We…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Growth Shares

3 mistakes I now avoid when choosing which growth stocks to buy

Jon Smith runs through some of the lessons he's learnt the hard way over the years about what to look…

Read more »